Our Pipeline

Advancing a robust pipeline built in-house

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Phase 3

Upcoming Milestones

Oncology

Porcupine Inhibitor
(RXC004)

Find out more

Genetically selected MSS mCRC mono + nivolumab combo

Porcupine

Topline data – from H1 2023

Genetically selected pancreatic cancer
Unselected biliary cancer mono + PD1 combo

Porcupine2
Fibrosis

ROCK2
Selective Inhibitor
(RXC007)

Find out more

Idiopathic pulmonary fibrosis (IPF)

Phase 2a topline data – H2 2023

GI-targeted
ROCK Inhibitor
(RXC008)

Find out more

Fibrostenotic Crohn’s Disease

IND/CTA submission – end 2023

Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Find out more

Fibrosis, Cancer-associated fibrosis

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Wholly-owned)

Oncology & Fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Find out more

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Find out more

Oncology

Sold to Jazz Pharmaceuticals

MAPK Pathway
Target

Oncology

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our Pipeline

Oncology

Porcupine Inhibitor
(RXC004)

Porcupine
Phase 2

Genetically selected MSS mCRC mono + nivolumab combo

Read more

UPCOMING MILESTONES

Topline data – from H1 2023

Porcupine2
Phase 2

Genetically selected pancreatic cancer
Unselected biliary cancer mono + PD1 combo

Fibrosis

ROCK2
Selective Inhibitor
(RXC007)

Phase 2

Idiopathic pulmonary fibrosis (IPF)

Read more

UPCOMING MILESTONES

Phase 2a topline data – H2 2023

GI-targeted
ROCK Inhibitor
(RXC008)

Preclinical

Fibrostenotic Crohn’s Disease

Read more

UPCOMING MILESTONES

IND/CTA submission – end 2023

Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Research

Fibrosis, Cancer-associated fibrosis

Read more

UPCOMING MILESTONES

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Wholly-owned)

Research

Oncology & Fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Preclinical

Idiopathic pulmonary fibrosis (IPF)

Read more

UPCOMING MILESTONES

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Preclinical

Oncology

Read more

UPCOMING MILESTONES

Sold to Jazz Pharmaceuticals

MAPK Pathway
Target

Research

Oncology

UPCOMING MILESTONES

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase